Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020

• Published in: Viruses 2022-10, Vol.14 (11), p.2321
• Main Authors: Mabilo, Prince, Mthiyane, Hloniphile, Simane, Andiswa, Subramoney, Kathleen, Treurnicht, Florette Kathleen
• Format: Article
• Language: English
• Subjects: Amino acids; Antibodies; antigenic sites; Communicable Diseases; Distribution; F gene; F protein; Fusion protein; Gene amplification; Genetic aspects; Genomes; Genotype; Genotypes; Glycoproteins; Glycosylation; HIV; Human immunodeficiency virus; Humans; Infant; Infections; Intensive care units; Maximum likelihood method; Monoclonal antibodies; Mortality; Mutation; Next-generation sequencing; palivizumab; Patients; Peptides; Phylogenetics; Phylogeny; Population; Proteins; respiratory; Respiratory syncytial virus; Respiratory Syncytial Virus Infections - epidemiology; Respiratory Syncytial Virus, Human - genetics; RSV; Sample size; Software; South Africa; South Africa - epidemiology; Strains (organisms); Testing; Vaccines; Viral Fusion Proteins - genetics; Viral infections
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v14112321

Respiratory syncytial virus (RSV) is classified into RSV-A and RSV-B, which are further classified into genotypes based on variability in the G gene. The fusion (F) protein is highly conserved; however, variability within antigenic sites has been reported. This study aimed to characterise F proteins from RSV strains detected in South Africa from 2019 to 2020. Patients of all ages, from whom respiratory samples were submitted to the National Health Laboratory Service at Charlotte Maxeke Johannesburg Academic Hospital, South Africa during 2019 to 2020, were included. Complete RSV F genes were amplified for next-generation sequencing. MEGA X software was used for phylogenetic analysis. The overall prevalence of RSV was 5.8% (101/1734). Among 101 RSV positive samples only 69.3% (70/101) were available for characterization of the RSV F protein gene. Among cases included for F gene characterisation, viral co-infections were observed in 50% (35/70) and 25.7% (18/70) were admitted to intensive care units (ICU). About 74.2% (23/31) of F gene sequences cluster with other African NA1/ON1 genotypes. At antigenic site I, the V384I mutation was replaced by V384T in South African strains. The S275F mutation was seen in a single South African strain. The N120 N-linked glycosylation site was present in 25.8% (8/31) of RSV-A F proteins described in this study. For the first time, we detected the rare S275F mutation that is associated with palivizumab resistance.